Harald F. Stock

Consilient Health Ltd. engages in the manufacture and distribution of pharmaceuticals. The private company is based in Clonskea, Ireland, and has subsidiaries in the United Kingdom. Luke Crosbie has been the CEO of the Irish company since 2005.

Vitanova Biomedical, Inc. is a biotechnology company based in the United States that focuses on improving the lives of cancer patients and healthcare professionals. The private company is based in Kerrville, TX. The company aims to achieve this through the development and commercialization of their novel light-activated intracellular acidosis platform cancer therapy. Vitanova Biomedical is currently working on preclinical evidence to support progress towards regulatory clearance and market commercialization. The company was founded by Matt Gdovin and Greg Espenhover. Tom Roberts has been the CEO of the company since 2016.

Vitanova Biomedical, Inc. is a biotechnology company based in the United States that focuses on improving the lives of cancer patients and healthcare professionals. The private company is based in Kerrville, TX. The company aims to achieve this through the development and commercialization of their novel light-activated intracellular acidosis platform cancer therapy. Vitanova Biomedical is currently working on preclinical evidence to support progress towards regulatory clearance and market commercialization. The company was founded by Matt Gdovin and Greg Espenhover. Tom Roberts has been the CEO of the company since 2016.

Vitanova Biomedical, Inc. is a biotechnology company based in the United States that focuses on improving the lives of cancer patients and healthcare professionals. The private company is based in Kerrville, TX. The company aims to achieve this through the development and commercialization of their novel light-activated intracellular acidosis platform cancer therapy. Vitanova Biomedical is currently working on preclinical evidence to support progress towards regulatory clearance and market commercialization. The company was founded by Matt Gdovin and Greg Espenhover. Tom Roberts has been the CEO of the company since 2016.

Quantum Diamond Technologies, Inc. develops and commercializes nanoscale devices. The company is headquartered in Somerville, MA.

Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX.

Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany.

Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX.

Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany.

Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany.

Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX.

Domus Diagnostics, Inc. is a company that aims to create affordable, user-friendly, accurate, and rapid tests for infectious diseases to address the needs raised by current and future public health crises. Domus Diagnostics seeks to change how infectious disease testing is done worldwide, with the goal of providing home testing for everyone, everywhere, to prevent future pandemics. The company was founded by John Reif, Harald F. Stock, and Xin Song, and is co-located in Durham and Park City, UT, with a product testing lab at the Research Triangle Park in North Carolina.

Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany.

Quantum Diamond Technologies, Inc. develops and commercializes nanoscale devices. The company is headquartered in Somerville, MA.

Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX.

Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany.

Quantum Diamond Technologies, Inc. develops and commercializes nanoscale devices. The company is headquartered in Somerville, MA.

Domus Diagnostics, Inc. is a company that aims to create affordable, user-friendly, accurate, and rapid tests for infectious diseases to address the needs raised by current and future public health crises. Domus Diagnostics seeks to change how infectious disease testing is done worldwide, with the goal of providing home testing for everyone, everywhere, to prevent future pandemics. The company was founded by John Reif, Harald F. Stock, and Xin Song, and is co-located in Durham and Park City, UT, with a product testing lab at the Research Triangle Park in North Carolina.

Consilient Health Ltd. engages in the manufacture and distribution of pharmaceuticals. The private company is based in Clonskea, Ireland, and has subsidiaries in the United Kingdom. Luke Crosbie has been the CEO of the Irish company since 2005.

Consilient Health Ltd. engages in the manufacture and distribution of pharmaceuticals. The private company is based in Clonskea, Ireland, and has subsidiaries in the United Kingdom. Luke Crosbie has been the CEO of the Irish company since 2005.

Consilient Health Ltd. engages in the manufacture and distribution of pharmaceuticals. The private company is based in Clonskea, Ireland, and has subsidiaries in the United Kingdom. Luke Crosbie has been the CEO of the Irish company since 2005.

Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany.

Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX.

Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX.

Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany.

Domus Diagnostics, Inc. is a company that aims to create affordable, user-friendly, accurate, and rapid tests for infectious diseases to address the needs raised by current and future public health crises. Domus Diagnostics seeks to change how infectious disease testing is done worldwide, with the goal of providing home testing for everyone, everywhere, to prevent future pandemics. The company was founded by John Reif, Harald F. Stock, and Xin Song, and is co-located in Durham and Park City, UT, with a product testing lab at the Research Triangle Park in North Carolina.

Quantum Diamond Technologies, Inc. develops and commercializes nanoscale devices. The company is headquartered in Somerville, MA.

Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX.

Consilient Health Ltd. engages in the manufacture and distribution of pharmaceuticals. The private company is based in Clonskea, Ireland, and has subsidiaries in the United Kingdom. Luke Crosbie has been the CEO of the Irish company since 2005.